Zions Bancorporation N.A. Raises Stock Position in Kenvue Inc. (NYSE:KVUE)

Zions Bancorporation N.A. raised its position in Kenvue Inc. (NYSE:KVUE) by 13.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 223,555 shares of the company’s stock after purchasing an additional 26,026 shares during the quarter. Zions Bancorporation N.A.’s holdings in Kenvue were worth $4,773,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Grove Bank & Trust lifted its holdings in Kenvue by 438.4% in the fourth quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock valued at $25,000 after acquiring an additional 947 shares during the last quarter. Geneos Wealth Management Inc. purchased a new stake in Kenvue in the fourth quarter valued at $29,000. SRS Capital Advisors Inc. lifted its stake in shares of Kenvue by 67.4% in the 4th quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company’s stock valued at $30,000 after purchasing an additional 571 shares during the last quarter. Fortitude Family Office LLC grew its holdings in shares of Kenvue by 106.6% during the 4th quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock worth $32,000 after purchasing an additional 777 shares during the period. Finally, Versant Capital Management Inc increased its position in shares of Kenvue by 300.8% during the 4th quarter. Versant Capital Management Inc now owns 1,920 shares of the company’s stock worth $41,000 after purchasing an additional 1,441 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Price Performance

Shares of NYSE KVUE opened at $23.38 on Tuesday. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. The company has a market cap of $44.68 billion, a price-to-earnings ratio of 44.10, a price-to-earnings-growth ratio of 2.62 and a beta of 1.25. The stock’s 50-day moving average is $22.13 and its two-hundred day moving average is $22.44. Kenvue Inc. has a 1-year low of $17.67 and a 1-year high of $24.46.

Kenvue (NYSE:KVUE) last released its earnings results on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. Analysts forecast that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th were issued a $0.205 dividend. The ex-dividend date was Wednesday, February 12th. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.51%. Kenvue’s payout ratio is 154.72%.

Analysts Set New Price Targets

KVUE has been the topic of a number of recent analyst reports. Citigroup decreased their target price on shares of Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a research report on Wednesday, January 15th. Evercore ISI began coverage on shares of Kenvue in a report on Monday. They issued an “in-line” rating and a $25.00 price objective on the stock. Piper Sandler lifted their target price on shares of Kenvue from $24.00 to $27.00 and gave the company an “overweight” rating in a report on Monday, February 24th. Deutsche Bank Aktiengesellschaft cut Kenvue from a “buy” rating to a “hold” rating and decreased their price target for the stock from $25.00 to $24.00 in a research note on Thursday, December 12th. Finally, UBS Group dropped their price objective on Kenvue from $23.00 to $21.00 and set a “neutral” rating for the company in a research note on Friday, February 7th. One analyst has rated the stock with a sell rating, eight have issued a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $23.85.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.